Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most grapefruit/statin interaction mechanism statements align with the provided label excerpts (CYP3A4 metabolism and increased atorvastatin concentrations). However, several claims go beyond the label’s level of specificity (e.g., furanocoumarins, “not all citrus fruits,” “large amounts of any citrus fruit,” and patent-expiration statements), and some preventive counseling details are not fully supported as written.
Category Scores
Accurate Statements
Grapefruit can interact with statins such as Lipitor (atorvastatin).
Supported by 7.2 Grapefruit Juice: components inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
CYP3A4 plays a crucial role in metabolizing statins, including atorvastatin.
Supported by 7.1 (and 12.3 pharmacokinetics excerpt): LIPITOR is metabolized by CYP3A4; in vitro studies suggest importance of metabolism by CYP3A4.
By slowing atorvastatin metabolism, grapefruit can increase Lipitor levels in the bloodstream.
Supported by 7.2: grapefruit juice components inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Increased Lipitor levels from grapefruit can potentially lead to an increased risk of side effects.
Partially supported: 7.1 indicates CYP3A4 inhibition can increase plasma concentrations; 5.1 notes increased risk of myopathy/rhabdomyolysis with concomitant CYP3A4 inhibitor use. The excerpt does not explicitly link grapefruit-specific increased levels to “side effects” generally, but the increase in risk of adverse outcomes with increased concentrations is consistent with label warnings.
Patients taking Lipitor should avoid or limit consumption of grapefruits and other citrus fruits.
Partially supported: 7.2 and 17.1 advise risk increased with consuming larger quantities of grapefruit juice (>1 liter) and mention grapefruit juice. The label excerpts provided do not support extending advice to “other citrus fruits.”
The patent for Lipitor (atorvastatin) has expired in various countries.
No label support assessed because this is not contained in the provided prescribing-information excerpts; no label section provided addresses patents.
This patent expiration does not affect the risk of interactions with citrus fruits.
No label support assessed because this is not contained in the provided prescribing-information excerpts; no label section provided addresses patents.
Unsupported Statements
Grapefruit contains furanocoumarins that inhibit the cytochrome P450 3A4 (CYP3A4) enzyme.
The provided label excerpts (notably 7.2) do not name furanocoumarins or specify that those constituents inhibit CYP3A4; they only state grapefruit juice contains components that inhibit CYP3A4.
Not all citrus fruits interact with Lipitor.
The provided label excerpts address grapefruit juice specifically; they do not state anything about other citrus fruits generally.
Lemons and limes are less likely to cause significant interactions with statins than grapefruit.
No provided label excerpt compares lemons/limes to grapefruit or addresses interactions with lemons/limes.
Eating large amounts of any citrus fruit can lead to increased consumption of furanocoumarins.
No provided label excerpt supports either that other citrus fruits increase furanocoumarins or that such consumption affects atorvastatin exposure.
Patients taking Lipitor should avoid or limit consumption of grapefruits and other citrus fruits.
While limiting grapefruit juice is supported, the label excerpts do not support extending this recommendation to “other citrus fruits.”
The patent for Lipitor (atorvastatin) has expired in various countries.
No provided prescribing-information excerpt addresses patent status.
This patent expiration does not affect the risk of interactions with citrus fruits.
No provided prescribing-information excerpt addresses how patent status affects interaction risk.
Contradictions
Important Omissions
The label excerpt specifies a quantitative limit for grapefruit juice in counseling (“larger quantities (>1 liter) of grapefruit juice”) but the AI claims do not reflect the label’s quantitative threshold.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
General grapefruit/atorvastatin interaction is supported, but the additional broad claims about “other citrus fruits” and mechanistic details (furanocoumarins) are not supported by the provided label excerpts. The unsupported patent-related statements are nonclinical but do not affect drug safety directly.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts (furanocoumarins wording; interaction claims about other citrus fruits; lemon/lime comparisons; patent-related statements). Preventive counseling is broader than label excerpts (grapefruit vs “other citrus fruits”).
Suggested Improvement
Limit interaction counseling to what the label excerpts support: grapefruit juice contains components that inhibit CYP3A4 and can increase atorvastatin concentrations, with counseling that risk is increased with larger quantities (>1 liter/day). Remove furanocoumarins-specific wording and any generalization to other citrus fruits or patent-status statements unless supported elsewhere in the labeling.